Focus: Emmecell is a public-stage biotechnology company focused on cell therapies for ophthalmology, headquartered in Menlo Park, CA. The company is early-stage with a pipeline concentrated in corneal and lens pathologies.
Profile data last refreshed Just now · AI intelligence enriched 2w ago
No open roles listed right now. Follow Emmecell to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Emmecell
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Emmecell's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease - Ophthalmology Times Europe
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease Ophthalmology Times Europe
Emmecell Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EO2002 for the Treatment of Corneal Endothelial Disease - Business Wire
Emmecell Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EO2002 for the Treatment of Corneal Endothelial Disease Business Wire
Emmecell Secures Strategic Financing Round With Participation From Bausch + Lomb - Eyewire+
Emmecell Secures Strategic Financing Round With Participation From Bausch + Lomb Eyewire+
Emmecell Announces Closing of Strategic Financing - Yahoo Finance
Emmecell Announces Closing of Strategic Financing Yahoo Finance
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company